Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update

Bertrand Coiffier, MD, PhD, Barbara Pro, MD, Miles Prince, MD, FRACP, FRCPA, Francine M. Foss, MD, Lubomir Sokol, MD, Ph.D, Matthew Greenwood, MD, FRACP, FRCPA, Dolores Caballero, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, MD, Swaminathan Padmanabhan, MD, Andrei R. Shustov, MD, Tina Nielsen, MD, PhD, Jean Nichols, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 3641.

https://doi.org/10.1182/blood.V120.21.3641.3641

Published: 2012

Journal Articles

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Simon J. Harrison, Hang Quach, Emma Link, John F. Seymour, David S. Ritchie, Sam Ruell, Joanne Dean, Henry Januszewicz, Ricky Johnstone, Paul Neeson, Michael Dickinson, Jean Nichols, H. Miles Prince

Blood (2011) 118 (24): 6274–6283.

https://doi.org/10.1182/blood-2011-03-339879

Published: 2011

Includes: Supplemental data

Journal Articles

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Bertrand Coiffier, MD, Barbara Pro, MD, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Francine M. Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, Swaminathan Padmanabhan, MBBS, MD, Andrei R. Shustov, MD, Jean Nichols, PhD, Susan Carroll, John Balser, PhD, Steven M. Horwitz, MD

Blood (2011) 118 (21): 591.

https://doi.org/10.1182/blood.V118.21.591.591

Published: 2011

Journal Articles

Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin

C.J. Godfrey, PhD, Christopher H. Cabell, MD, MHS, FACC, Barbara Balser, VMD, Julie Wolfson, MPH, Jean Nichols, PhD, Howard A. Burris, III, MD

Blood (2011) 118 (21): 2680.

https://doi.org/10.1182/blood.V118.21.2680.2680

Published: 2011

Journal Articles

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

Bertrand Coiffier, MD, PhD, Barbara Pro, MD, H. Miles Prince, MD, FRACP, FRCPA, Francine M Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, MD, Swaminathan Padmanabhan, MD, Andrei Shustov, MD, Jean Nichols, Susan Carroll, John Balser, PhD, Steven M Horwitz, MD

Blood (2010) 116 (21): 114.

https://doi.org/10.1182/blood.V116.21.114.114

Published: 2010

Journal Articles

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Sean Whittaker, MD, FRCP, Ellen J Kim, MD, Miles Prince, Marie France Demierre, MD, Cynthia Giver, Sagar Lonial, MD, Richard Piekarz, MD, PhD, Youn H Kim, MD, Jean Nichols, PhD, Darrell Nix, Ph.D., Susan Bates, MD

Blood (2009) 114 (22): 3701.

https://doi.org/10.1182/blood.V114.22.3701.3701

Published: 2009

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Susan Bates, MD, Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, William Douglas Figg, Sr., PharmD, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRAPC, Mark Kirschbaum, MD, John P. Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Maryalice Stetler- Stevenson, MD, PhD, Alex Ling, MD, Jean Nichols, PhD

Blood (2008) 112 (11): 1568.

https://doi.org/10.1182/blood.V112.11.1568.1568

Published: 2008

NARROW

Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only